Nanobiotix S.A. logo
Nanobiotix S.A. NBTX
$ 30.04 -8.62%

Annual report 2024
added 03-21-2026

report update icon

Nanobiotix S.A. Market Cap 2011-2026 | NBTX

As of April 07, 2026 Nanobiotix S.A. has a market cap of $ 286 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Nanobiotix S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 262 B 405 M - - - - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
262 B 405 M 131 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
322 M $ 1.36 -2.52 % $ 362 M britainBritain
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
2.82 B $ 20.25 -0.54 % $ 2.83 B franceFrance
Dyadic International Dyadic International
DYAI
31.5 M $ 0.87 0.59 % $ 31.5 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.78 4.83 % $ 9.09 B australiaAustralia
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
15.8 M $ 2.6 -2.26 % $ 16.3 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Fate Therapeutics Fate Therapeutics
FATE
187 M $ 1.14 -4.2 % $ 135 M usaUSA
Forte Biosciences Forte Biosciences
FBRX
335 M $ 26.44 - $ 342 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
169 M $ 6.16 -4.05 % $ 176 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
4.43 B $ 14.46 0.03 % $ 4.46 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
539 K $ 7.57 -3.32 % $ 480 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Galectin Therapeutics Galectin Therapeutics
GALT
178 M $ 2.28 -11.13 % $ 146 M usaUSA
Gilead Sciences Gilead Sciences
GILD
183 B $ 138.34 -1.28 % $ 172 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
1.25 M $ 0.54 4.28 % $ 503 K israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
Genmab A/S Genmab A/S
GMAB
25 B $ 27.14 -2.2 % $ 17 B danmarkDanmark
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
BioNTech SE BioNTech SE
BNTX
62.9 B $ 88.2 -3.37 % $ 27.2 B germanyGermany
Gossamer Bio Gossamer Bio
GOSS
107 M $ 0.32 -7.11 % $ 73.1 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
226 M $ 1.62 -3.29 % $ 190 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
8.42 B $ 7.98 -3.04 % $ 6.83 B spainSpain
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
8.08 B $ 3.5 -1.13 % $ 236 B britainBritain
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
GT Biopharma GT Biopharma
GTBP
2.59 M $ 0.41 -8.56 % $ 2.26 M usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
40.8 B $ 316.69 -4.13 % $ 41.5 B usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
9.66 B $ 63.72 1.01 % $ 7.64 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
13.1 M - 4.14 % $ 49.1 M usaUSA
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
1.61 B $ 27.53 -0.67 % $ 1.58 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 4.53 1.0 % $ 726 M britainBritain
Atreca Atreca
BCEL
49 M - -11.76 % $ 5.79 M usaUSA